Breakthrough status in hand, Prosensa launches $78m IPO

00:20 EDT 28 Jun 2013 | SCRIP

The neuromuscular disease results from incorrect coding in the dystrophin gene and patients generally die within a few years of reaching adulthood.

Original Article: Breakthrough status in hand, Prosensa launches $78m IPO

NEXT ARTICLE

More From BioPortfolio on "Breakthrough status in hand, Prosensa launches $78m IPO"

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

Bioinformatics
Latest News Clinical Trials Research Drugs Reports Corporate
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Advertisement

Searches Linking to this Story